“In that group of 120 to 139, where there is a lot of debate on whether intensive blood pressure control would result in more side effects, more risk of falls or dizziness, et cetera, of NT-proBNP may ...

March 29, 2009 (Orlando, Florida) — Using individualized levels of the biomarker NT-proBNP to guide the treatment of patients with chronic heart failure did not improve their morbidity or ...

At this year's congress of the American Heart Association (AHA) in Chicago, November 13-17, new data on the use of NT-proBNP to guide heart failure therapy was presented by study investigators from ...

The aim of this study was to assess the value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in predicting late cardiotoxicity in patients treated with not-high-dose chemotherapy (NHDC ...

NT-proBNP was the strongest independent predictor of events in a new study. The authors suggest it may be best measured at six weeks' post-ACS, while CRP measurement may be useful at later follow-up.

By week 4, improvements in plasma NT-proBNP levels were already being seen vs the comparator group, and this was sustained through week 24 Treatment history did not have an impact on NT-proBNP ...

Moreover, NT-proBNP did not significantly modify the neutral treatment effect of sacubitril/valsartan relative to ramipril (P for interaction = .46), researchers reported.

Patients receiving BNP-guided treatment had a significant reduction in all-cause mortality (hazard ratio 0.69, 95% CI 0.55-0.86), with an NNT of 12-40 for one year, assuming 80% survival in the ...

CHICAGO — An autologous point-of-care cell therapy for adults with ischemic HF with reduced ejection fraction was safe and may be beneficial for select candidates, though a pivotal study did not ...

G. Michael Felker, MD, from the Duke Clinical Research Institute in Durham, NC, and colleagues randomized patients to an NT-proBNP-guided strategy, in which heart failure therapy was titrated with ...

To explore the association of urinary N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations and closure of patent ductus arteriosus (PDA) in preterm infants. Blinded prospective ...

NT-proBNP is a predictor of CV risk in arthritis patients ... Treatment options that help manage early inflammation in patients with RA may ensure that the long-term CV risk associated ...